8-K: Cyclo Therapeutics Secures $3 Million in Convertible Note Financing from Rafael Holdings

Cyclo Therapeutics has entered into a seventh amended agreement with Rafael Holdings, securing a $3 million convertible promissory note to be used for working capital and general corporate purposes.

Summary

• Cyclo Therapeutics has secured a $3 million convertible promissory note from Rafael Holdings.
• This agreement is the seventh amendment to a series of note purchase agreements between the two companies.
• The note matures on February 15, 2025, and carries an annual interest rate of 5%, payable upon maturity.
• The principal amount of the note is convertible into shares of Cyclo Therapeutics' common stock under certain conditions.
• These conditions include a qualified financing event, a sale transaction, or at the option of Rafael Holdings.
• The proceeds from the note will be used for working capital and general corporate purposes.
• Rafael Holdings currently holds approximately 39.5% of Cyclo Therapeutics' common stock.
• There is a pending merger agreement between Cyclo Therapeutics and a subsidiary of Rafael Holdings, subject to shareholder approval.

Sentiment

Score: 4

Explanation: The document indicates a need for ongoing financing, which is a negative signal. The repeated amendments to the note purchase agreement and the pending merger suggest a complex financial situation. While the funding is positive, the reliance on debt and the potential for dilution are concerning.

Positives

• Cyclo Therapeutics has secured additional funding of $3 million to support working capital and general corporate purposes.
• The convertible note provides flexibility for both Cyclo Therapeutics and Rafael Holdings.
• The funding demonstrates continued support from Rafael Holdings, a major shareholder.

Negatives

• The company is relying on debt financing, which may indicate challenges in raising equity capital.
• The convertible nature of the note could lead to dilution of existing shareholders if converted to equity.
• The company has a history of amending and restating note purchase agreements with Rafael Holdings, which may indicate ongoing financial challenges.

Risks

• The company's ability to repay the note depends on its financial performance and ability to secure additional funding.
• The conversion of the note could dilute existing shareholders.
• The merger with Rafael Holdings is subject to shareholder approval and may not be completed.
• Failure to meet the terms of the note could trigger an event of default and accelerate repayment obligations.

Future Outlook

The company intends to use the proceeds of the note for working capital and general corporate purposes, and is also subject to a pending merger with a subsidiary of Rafael Holdings.

Management Comments

• The company intends to use the proceeds of the Note for working capital and general corporate purposes.

Industry Context

This financing activity is not uncommon for biotech companies that are in the development stage and require capital to fund operations and research. The repeated amendments to the note purchase agreement and the pending merger suggest a strategic relationship with Rafael Holdings.

Comparison to Industry Standards

• Many biotech companies rely on convertible debt financing, especially during early stages of development, as it provides a bridge to future equity raises or strategic transactions.
• The 5% interest rate is relatively standard for this type of financing, but the conversion terms are specific to the agreement between Cyclo Therapeutics and Rafael Holdings.
• The repeated amendments to the note purchase agreement are not typical and may indicate a need for ongoing financial support from Rafael Holdings.
• The pending merger with a subsidiary of Rafael Holdings is a significant event that could change the company's structure and future prospects, similar to other biotech companies that have been acquired by larger entities.

Related Party Transactions

• The convertible note agreement is a related party transaction with Rafael Holdings, which owns approximately 39.5% of Cyclo Therapeutics' common stock.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted to equity.
• Employees may be impacted by the company's financial situation and the pending merger.
• Creditors may be impacted by the company's debt obligations.
• Customers and suppliers may be impacted by the company's financial stability and future direction.

Next Steps

• The company will use the funds for working capital and general corporate purposes.
• The company will need to manage the debt and potential conversion of the note.
• The company will need to seek shareholder approval for the proposed merger with Rafael Holdings' subsidiary.

Key Dates

Keywords

convertible note, financing, Rafael Holdings, merger, working capital, promissory note, common stock, dilution, debt financing